Indications › MASH / NAFLD › semaglutide

semaglutide in MASH / NAFLD

semaglutide is not approved in the US for MASH / NAFLD, and has 20 trials on file here in this condition. 7 of them are phase 3 or later. The next scheduled result is 2026-12. Being studied in a condition is not the same as being approved for it; most such programmes end without an approval.

20 registered trials study semaglutide (Ozempic, Rybelsus, Wegovy) in MASH / NAFLD, 9 of them still active and 2 in phase 3. The next is due to report 2026-12-31.

Trials on file: 20
Active: 9
Active phase 3: 2
Participants in active trials: 2,326
Sponsors: 15
Scheduled readouts: 4

Scheduled to report

Dates are filed by the sponsor and move often. Each links to its own record and change history.

Est. completion	Trial	Phase	Participants
2026-12-31	Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM NCT06005012 · University of California, San Diego	P2	120
2026-12-31	A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD） NCT06884293 · Innovent Biologics (Suzhou) Co. Ltd.	P3	479
2027-04-30	A Study of CS060380 Tablets in Patients With MASH and Obesity NCT07466017 · Cascade Pharmaceuticals, Inc	P2	130
2027-09-03	Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES) NCT03884075 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	P2	104

All trials on file

Every registered trial of semaglutide grouped under MASH / NAFLD, largest first. Grouping follows the registry’s own condition wording.

Trial	Status	Phase	Sponsor
Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH) NCT04822181	Active, not recruiting	P3	Novo Nordisk A/S
Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH) NCT05016882	Completed	P2	Novo Nordisk A/S
A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD） NCT06884293	Active, not recruiting	P3	Innovent Biologics (Suzhou) Co. Ltd.
Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) NCT04971785	Completed	P2	Gilead Sciences
A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013) NCT05877547	Completed	P2	Merck Sharp & Dohme LLC
Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis. NCT02970942	Completed	P2	Novo Nordisk A/S
Combined Active Treatment in Type 2 Diabetes With NASH NCT04639414	Completed	P4	German Diabetes Center
Semaglutide in Nonalcoholic Fatty Liver Disease NCT05813249	Completed	P4	Zagazig University
A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001) NCT04944992	Completed	P2	Merck Sharp & Dohme LLC
A Study of CS060380 Tablets in Patients With MASH and Obesity NCT07466017	Active, not recruiting	P2	Cascade Pharmaceuticals, Inc
Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM NCT06005012	Active, not recruiting	P2	University of California, San Diego
Fibrosis Lessens After Metabolic Surgery NCT06374875	Recruiting	P4	The Cleveland Clinic
Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH) NCT03987074	Completed	P2	Gilead Sciences
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES) NCT03884075	Recruiting	P2	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver Damage NCT03987451	Completed	P2	Novo Nordisk A/S
Treating PCOS With Semaglutide vs Active Lifestyle Intervention NCT03919929	Completed	P2/P3	University of Colorado, Denver
Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease NCT05067621	Active, not recruiting	P2	Yale University
Semaglutide vs Sitagliptin NCT05195944	Active, not recruiting	P4	University Health Network, Toronto
Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study) NCT04216589	Completed	P2	National Institute of Allergy and Infectious Diseases (NIAID)
Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant NCT05424003	Recruiting	P2	University of Virginia

See the full record for semaglutide, or every molecule being studied in MASH / NAFLD. These are registered trials, nothing more. Most drugs tested in a new condition never get approved for it, and plenty of these will report nothing useful.